Pregnant Women vaccine safety surveillance Pertussis vaccine safety surveillance data From 1 July 2018, maternal pertussis vaccine is being funded for pregnant women under the National Immunisation Program. AusVaxSafety is monitoring the safety of maternal pertussis vaccines in the days following immunisation. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here. Last updated: 10/01/2020 7,812 Pregnant women responded to an SMS about their health a few days after their maternal pertussis vaccinations. 93.9% reported no adverse events 93.9% reported no adverse events 6.1% reported any adverse event, including... 0.5% who reported going to a doctor or emergency department in the days after vaccination.The adverse events they reported were similar to the types of adverse events reported overall 477 Pregnant women reported one or more adverse events. The most commonly reported were: These symptoms are known to occur after vaccination. They are generally mild and short-lived. Influenza vaccine safety Surveillance data Surveillance of 2019 influenza vaccine safety commenced from 1 April 2019. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here. 3,718 Pregnant women responded to an SMS about their health a few days after their influenza vaccinations. 95.5% reported no adverse events 95.5% reported no adverse events 5.5% reported any adverse event, including... 0.5% who reported going to a doctor or emergency department in the days after vaccination.The adverse events they reported were similar to the types of adverse events reported overall 204 Pregnant women reported one or more adverse events. The most commonly reported were: These symptoms are known to occur after vaccination. They are generally mild and short-lived.
